The rapidly evolving treatment landscape of advanced prostate, bladder, and renal cell carcinomas

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer treatment and research communications 2020, Vol.24, p.100190-100190, Article 100190
Hauptverfasser:	Hahn, Andrew W., Agarwal, Neeraj
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers, Tumor - antagonists & inhibitors Biomarkers, Tumor - genetics Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - genetics Carcinoma, Renal Cell - mortality Carcinoma, Renal Cell - pathology Carcinoma, Transitional Cell - drug therapy Carcinoma, Transitional Cell - genetics Carcinoma, Transitional Cell - mortality Carcinoma, Transitional Cell - pathology Clinical Trials as Topic Germ-Line Mutation Humans Kidney Neoplasms - drug therapy Kidney Neoplasms - genetics Kidney Neoplasms - mortality Kidney Neoplasms - pathology Male Poly(ADP-ribose) Polymerase Inhibitors - pharmacology Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use Progression-Free Survival Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - genetics Prostatic Neoplasms, Castration-Resistant - mortality Prostatic Neoplasms, Castration-Resistant - pathology Recombinational DNA Repair - drug effects Recombinational DNA Repair - genetics Urinary Bladder Neoplasms - drug therapy Urinary Bladder Neoplasms - genetics Urinary Bladder Neoplasms - mortality Urinary Bladder Neoplasms - pathology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:
ISSN:	2468-2942 2468-2942
DOI:	10.1016/j.ctarc.2020.100190